Published online before print October 22, 2007, doi: 10.1161/CIRCULATIONAHA.106.686477
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2269-2274.)
© 2007 American Heart Association, Inc.
Epidemiology |
Ankle-to-Brachial Index and Dementia
The Honolulu-Asia Aging Study
From Laval University Geriatrics Research Unit, Centre de recherche du CHA, and Faculty of Pharmacy, Laval University, Quebec City, Quebec, Canada (D.L.); Pacific Health Research Institute and Kuakini Medical Center, Honolulu, Hawaii (K.H.M., L.R.W.); and Neuroepidemiology Section, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Md (L.J.L.).
Correspondence to Dr Lenore J. Launer, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Gateway Building, Room 3C309, 7201 Wisconsin Ave, Bethesda, MD 20892–9205. E-mail launerl{at}nia.nih.gov
Received January 12, 2007; accepted September 6, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Measurement of the ankle-to-brachial index (ABI) is a noninvasive test to assess peripheral arterial disease. A low ABI is a strong correlate of cardiovascular disease and subsequent mortality. Evidence indicates the existence of vascular components in the pathogenesis of dementia. Here, we examine the association of ABI with dementia and subtypes.
Methods and Results— Data are from the Honolulu-Asia Aging Study (HAAS), a prospective community-based study of 3734 Japanese American men 71 to 93 years of age at baseline in 1991 to 1993. The analysis included 2588 men who were free of dementia at the first assessment, had an ABI measure, and were examined up to 2 more times for dementia between 1994 and 1999. The sample included 240 incident cases of dementia (144 of Alzheimer’s disease, 46 of vascular dementia, and 50 of dementia of other causes). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated from Cox proportional-hazards models with age as the time scale after adjustment for education, year of birth, high blood pressure, body mass index, diabetes mellitus, cholesterol concentration, smoking status, alcohol consumption, and apolipoprotein E 
4 allele. A low ABI was associated with an increased risk of dementia and vascular dementia (HR, 1.66; 95% CI, 1.16 to 2.37; and HR, 2.25; 95% CI, 1.07 to 4.73, respectively). ABI was weakly associated with Alzheimer’s disease (HR, 1.57; 95% CI, 0.98 to 2.53), particularly in the apolipoprotein E 4 carriers (HR, 1.43; 95% CI, 1.02 to 1.96).
Conclusions— These results suggest that ABI, a measure of atherosclerosis, is associated with the incidence of total dementia, vascular dementia, and Alzheimer’s disease in carriers of the apolipoprotein E 4 allele.
Key Words: aging • apolipoproteins • epidemiology • peripheral vascular disease • population • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Peripheral artery disease (PAD) is a common disorder in aging populations that could benefit from a number of preventive interventions. PAD, which results from the accumulation of atherosclerosis in the lower limbs, affects up to 30% of North Americans and Europeans >55 years of age, half of whom are asymptomatic.1 The ankle-to-brachial index (ABI) has proved to be the most effective and accurate noninvasive test to assess PAD.2 Modifiable risk factors associated with PAD include heavy smoking, hypertension, and diabetes mellitus. A low ABI has been reported to be a strong independent correlate of cardiovascular disease and subsequent mortality in older persons.3
Clinical Perspective p 2274
Although the influence of cerebrovascular disease on cognition is well established, the evidence that PAD may lead to cognitive loss or impairment is less well studied. In clinical settings, poorer performance on several neuropsychological tests, including measures of attention, psychomotor speed, and visuospatial and executive function, has been documented among amputees or other highly selected patients with PAD4–6 compared with control subjects, although inconsistently.7
Few epidemiological studies have examined the association of cognitive function and PAD in the general population. A PAD link to poorer performance of cognition has been reported in cross-sectional analyses that measured cognition with the Mini-Mental State Examination8,9; again, these results have not consistently been replicated.10,11 Two studies reported that subjects with a low ABI and an apolipoprotein (Apo) E 4 allele had the greatest cognitive decline compared with those with 1 or 0 of those risk factors.12,13 The ApoE 4 allele has been reported to modify the association of other cerebrovascular disease risk factors to cognitive function and Alzheimer’s disease (AD).14–16
It is not known whether PAD is associated with clinical dementia. Vascular risk factors, including atherogenic and stroke-related damage, are known to play a predominant role in vascular dementia (VaD), but there also is significant evidence of their involvement in AD.17 Therefore, we hypothesized that the ABI is associated with the risk of all dementia, VaD, and AD. In addition, we evaluated the potential effect modification of risk associated with ApoE 4.16
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
Data are from the Honolulu-Asia Aging Study (HAAS), which is a longitudinal community-based study derived from the Honolulu Heart Program (HHP), a study of cardiovascular disease in men of Japanese ancestry born between 1900 and 1919 who were living on the island of Oahu, Hawaii, at the time of the first examination.18 This examination was carried out from 1965 through 1968; subjects were reevaluated in 1968 to 1970 (examination 2) and in 1971 to 1974 (examination 3). A standardized clinical evaluation of several physical and laboratory functions was performed at all examinations; data on sociodemographic characteristics and medical history were collected by structured interview. The HAAS was initiated in 1991 to 1993 to coincide with the fourth examination of the HHP.19 Of the HHP cohort, 3734 subjects (80% of survivors) between 71 and 93 years of age agreed to participate in the HAAS when the first evaluation for dementia was performed. Subjects were evaluated for dementia on 2 other occasions in 1994 to 1996 (examination 5) and 1997 to 1999 (examination 6). The Kuakini Medical Center Institutional Review Committee approved the study, and all subjects, or their caretakers when subjects were demented, provided written informed consent.
Dementia Case Findings
At HAAS baseline (examination 4) and subsequent examinations, subjects were first screened for dementia with the 100-point Cognitive Abilities Screening Instrument,20 a combination of the Hasegawa Dementia Screening Scale, the Folstein Mini-Mental State Examination, and the Modified Mini-Mental State Test. Case finding was conducted according to a multistep procedure previously described,19 with the Cognitive Abilities Screening Instrument score used to determine subgroups for evaluation. The dementia evaluation included a neurological examination, neuropsychological testing, and an informant interview about changes in cognitive function and behavior. In subjects suspected to have dementia, a brain image was made and routine blood tests were conducted. On the basis of these data, a consensus diagnosis for dementia was given by the study neurologist and 2 physicians with expertise in dementia, according to the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria.21 Of the 3734 subjects evaluated at examination 4, 1095 subjects were positive for dementia; 20.1% of them were diagnosed as prevalent cases of dementia. Of the 2693 subjects evaluated at examination 5, 751 were screened positive; 19% of them were diagnosed as incident cases of dementia. Finally, of the 1982 subjects evaluated at examination 6, 307 were screened positive; 35% of them were diagnosed as incident cases of dementia.
Probable or possible AD was diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria.22 Mixed dementia involving AD as the primary cause was defined as possible AD. Definite AD can be diagnosed only with neuropathological data. The sensitivity of the clinical diagnosis of AD compared with autopsied brains has been previously examined in a subset of the HAAS sample; 65% of clinical AD cases had sufficient neuritic plaques to meet neuropathologically definite or probable AD criteria.23 VaD was diagnosed with the criteria of the California Alzheimer’s Disease Diagnostic and Treatment Centers.24 Other dementias included those caused by alcohol, brain tumor, subdural hematoma, Parkinson’s disease, Lewy body disease, Pick’s disease, trauma, vitamin B12 deficiency, hypothyroidism, progressive supranuclear palsy, and unknown cause.
ABI Measurement
The ABI was measured at HAAS baseline (1991 to 1993) according to a standard protocol.25,26 The brachial pressure was measured twice in the right arm, and the ankle (posterior tibial) pressure was measured twice in each ankle with subjects in the supine position by use of a handheld Doppler device (Huntleigh D500 Mini Dopplex Luton, Bedfordshire, Great Britain) attached to a standard sphygmomanometer. The means of the 2 measurements in the arm and each ankle were taken to calculate the ABI for both the left and right sides, and the lowest value of the ABI was chosen. A ratio <1 results from a relatively low ankle pressure, which may indicate subclinical atherosclerosis in lower extremity arteries. The validity criteria of the ABI as a screening tool for coronary heart disease have been measured; the sensitivity and specificity of an ABI <1 for coronary heart disease were 41% and 73%, respectively.27
Covariates and Potential Confounders
Covariates and potential confounders taken into consideration were measured at HAAS baseline. Cigarette smoking status was coded as never smoker, past smoker, and current smoker. Alcohol consumption was categorized into no alcohol, <15 g/d (<1 drink per day), 15 to 30 g/d (1 to 2 drinks per day), and 
30 g/d (3 drinks per day). Systolic and diastolic blood pressure values corresponded to the mean of 3 measurements made on the left arm with subjects in the seated position. High blood pressure was defined as systolic blood pressure 160 mm Hg, diastolic blood pressure 95 mm Hg, or the use of medications for hypertension. Total cholesterol, triglycerides, glucose, insulin, and a standard 2-hour oral glucose tolerance test were measured in specimens collected from subjects in a fasting state. Impaired glucose regulation, including impaired fasting glucose or impaired glucose tolerance, was defined as fasting blood glucose between 5.6 and 7.0 mmol/L (100 to 126 mg/dL) or 2-hour postload glucose between 7.8 and 11.1 mmol/L (140 to 200 mg/dL). Diabetes mellitus was defined as fasting blood glucose 7.0 mmol/L (126 mg/dL), 2-hour postload glucose 11.1 mmol/L (200 mg/dL), or the use of medications.28 Body mass index was calculated as the weight (kg) divided by the height (m) squared. ApoE genotyping was obtained by standard DNA amplification and restriction isotyping.29 All carriers of ApoE 4 were combined and coded as a binary variable, the presence/absence of ApoE 4. A variable for the history of cardiovascular disease relative to HAAS baseline was created using the information from the continuous surveillance of hospital discharge and death records on Oahu. A positive history referred to either a stroke or a coronary heart disease event before examination 4. Confounders with <5% missing values were replaced with missing-value dummy variables when variables were discrete or were given the mean value of the distribution of the study population when continuous.
Statistical Analyses
Characteristics of incident dementia cases and the cases negative for dementia were compared by use of the Kruskal-Wallis tests for continuous variables and 
2 tests for categorical variables after adjustment for age and education. ABI was studied 2 ways. First, we divided the variable into 3 categories: <0.90, the grouping that reflects PAD; 0.90 to 1.20, the referent group; and 1.20. This second cutoff was defined to take into account subjects having stiffened noncompressible peripheral vessels, like diabetics, which may show falsely elevated ABI values.30 To examine the linear relationship of ABI to dementia, we also converted ABI, which was relatively normally distributed, into a z score, with a mean of 0 and SD of 1 (range, –4.1 to 6.3). We tested for a nonlinear relationship by adding the ABI as its quadratic term to the model. The association between ABI and VaD was linear; the associations between ABI and all dementia and AD were nonlinear and treated accordingly.
The Cox proportional-hazards regression model with delayed entry and age as the time scale was used to identify and adjust for confounding variables.31 The age of onset was assigned at the mid point of the interval between the last examination without dementia and the first follow-up with dementia. Subjects who died or did not participate in subsequent follow-up examinations were censored as of the time of their last evaluation. Covariates included year of birth and education (model 1). In addition to model 1 variables, we included high blood pressure, diabetes mellitus, smoking status, alcohol consumption, cholesterol (coded in quintiles), body mass index, and ApoE 4 status in model 2, plus history of cardiovascular disease in model 3.
The proportional-hazards assumptions were tested graphically and by including the interaction of time with each covariate. The effect of year of birth did not follow the proportional-hazards model assumption, so it was entered as a 3-category stratum variable in all analyses; thus, all analyses are stratified by categories of birth year, and the final model results are summarized over these categories. Cutoffs of strata were picked to achieve a balanced distribution of cases and noncases. We further tested the effect modification by ApoE 4 status of dementia risk by stratifying the analysis according to ApoE 4 status (carrier versus noncarrier) and by formally testing the interaction term (ABIxApoE 4 status). Analyses were performed with the Statistical Analysis System version 9.1 software (SAS Institute Inc, Cary, NC).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Of the 3734 HAAS subjects, 226 were prevalent cases of dementia and were excluded. Of the remaining eligible subjects, 920 could not be included because of death (n=418), refusal of another case-finding examination (n=462), or missing data for ABI (n=40), leaving 2588 subjects for final analyses. Compared with those from the analytical sample, subjects with missing ABI or who refused were on average older (78.6 versus 76.9 years; P<0.001) and less educated (9.5 versus 10.8 years; P<0.001) at baseline.
The mean±SD age of subjects at baseline was 76.9±4.1 years. PAD, defined by an ABI <0.90, affected 271 subjects (10.5%) of the study sample. Over the 5.1 years of follow-up (range, 1.1 to 7.8 years), 2348 subjects remained nondemented, and 240 developed dementia; this included 144 cases of AD (103 probable AD and 41 possible AD with contributing cerebrovascular disease), 46 cases of VaD, and 50 cases resulting from other causes. The mean age at baseline was 79.6 years (SD, 4.8 years) for the AD group and 78.6 years (SD, 5.2 years) for the VaD group; this difference was not statistically different (P=0.24). Men who screened as demented at follow-up were significantly older at baseline (79.3 versus 76.6 years; higher proportion of men born between 1900 and 1912: 46.3% versus 23.4%), had fewer years of education (10.2 versus 10.9 years), showed a higher proportion of ApoE 4 (22.5% versus 18.0%), and had lower mean values of cholesterol, triglycerides, and body mass index (Table 1).
|
After adjustment for education and year of birth, ABI was significantly associated with the risk for total dementia and VaD (Table 2, model 1). After additional adjustment (Table 2, model 2), however, the risk for dementia was no longer significant. The risk of VaD increased significantly with each 1-SD unit reduction in ABI (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.07 to 2.00). Additional adjustment by history of cardiovascular disease (model 3) reduced the risk estimate by 13% (HR, 1.28; 95% CI, 0.93 to 1.75). Similar results on total dementia and VaD were observed when the distribution of ABI was divided into 3 categories. After full multivariate adjustment (model 2), subjects with PAD showed a 66% increase in risk of dementia and a >2-fold increase in risk of VaD (HR, 2.25; 95% CI, 1.07 to 4.73) compared with the referent group. This increased risk remained significant in model 3 for total dementia (HR, 1.62; 95% CI, 1.13 to 2.32). PAD was associated with the risk of AD in the simplest model (HR, 1.60; 95% CI, 1.01 to 2.53). The presence of stiffened vessels (ABI 1.20) was not associated with the risk of total dementia and subtypes.
|
Effect modification was tested in total dementia and AD with the simplest model (model 1) and with ABI as a continuous variable (Table 3). Given the small number of incident cases with ApoE 4 (n=7), effect modification was not tested in VaD. Among ApoE 4 carriers, the risk of AD increased significantly with each 1-SD unit reduction in ABI (HR, 1.43; 95% CI, 1.02 to 1.96). The risk of AD was not related to ABI in noncarriers of ApoE 4. No interaction was observed between ABI and ApoE 4 in total dementia.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study suggests that a low ABI was related to an increased risk of total dementia and VaD. In addition, a low ABI was associated with an increased risk of AD if subjects were carriers of ApoE
4. These results are based on a large community-based study of Japanese American men followed up extensively for >30 years for vascular risk factors and for >10 years for dementia. Limitations of this study need to be discussed when the data are interpreted. Of eligible subjects, 25.1% could not be included because they died (11.9%) or refused a follow-up examination (13.2%). Subjects excluded were, at baseline, slightly older and less educated, both risk factors for dementia, but also showed a 1.9% lower ABI mean value. Excluding decedents and nonresponders may have therefore underestimated the risks. Furthermore, subjects in this cohort were very old at baseline. Survival bias may have distorted results and further underestimated the risks because patients with more severe cases of PAD may have died of coronary heart disease before developing dementia. Second, given that the ABI is a noninvasive tool, it has been demonstrated that various factors may produce significant interobserver and intraobserver error in the measure.32 In the present study, the ABI was measured according to a protocol with trained technicians using a standardized methodology to reduce the error. These results could be limited because they were observed in a cohort consisting exclusively of men. Symptomatic PAD, defined as intermittent claudication, has been reported to be more common in men than women.33 However, the prevalence of PAD, defined by an ABI <0.90, has been shown to be higher in older women than men34 or not to vary by gender.35,36 No gender differences in the consequences of PAD have been reported. Third, results were not adjusted for the carotid intima-media thickness, which has been correlated to cognitive function37 and reported to be a definite risk factor for myocardial infarction and stroke in older people.38 On the other hand, one may argue that because carotid intima-media thickness is, like ABI, a marker of atherosclerosis, adjusting for this variable could create a problem of collinearity. Finally, analyses were restricted to small subsets of subjects, in particular when testing for effect modification; this may have biased the results toward the null hypothesis. Moreover, results on VaD and other dementia were based on small numbers of events and should be interpreted with caution.
These findings contribute uniquely to the growing body of evidence on vascular risk factors and dementia. Previous investigations4–11 of the relationship between PAD and cognitive function were based on cross-sectional designs, volunteers, or severe cases of PAD. Cognitive function was assessed with the Mini-Mental State Examination7–13 and/or neuropsychological tests.4–7,10,12,39 In relatively young cohorts, the prevalence10 and occurrence39 of intermittent claudication were associated with poor cognitive function. A cross-sectional association of PAD with cognition also was observed in population-based studies in older persons, including the Rotterdam Study8,13 and the Cardiovascular Health Study.12 Here, we show that PAD, as measured by ABI, is associated with an increased risk for dementia.
Reduced ABI was significantly associated with an increased risk of VaD. Potential mechanisms that might underlie this association include the progressive occlusion of arteries and vascular disease that leads to occlusion of the cerebral arteries, cerebral tissue loss, and cognitive decline. There also is evidence of a strong positive association between PAD and inflammation, which has been inferred in the pathogenesis of atherosclerosis40 and linked to the onset of dementia and AD.41 Although we expected an association of ABI with AD, it was weak in this analysis. It is possible that atherosclerosis per se is not as an essential vascular risk factor for cerebral disease found in AD compared with VaD cases. When results were further adjusted for stroke or coronary heart disease (model 3), these events had a major impact on VaD but almost none on AD. However, subjects with ApoE 4 and a low ABI were at a higher risk of AD compared with those with a higher ABI. Similar findings on the modification effect of ApoE 4 on the relationship of ABI to cognitive function have been reported in 2 other studies.12,13
Because there still is no cure for dementia, modifiable risk factors must be identified to delay its onset or progression. The ABI is an invaluable tool, showing high validity for the prediction of coronary heart disease and stroke. The present study found that a low ABI value was associated with the risk of VaD and total dementia. Preventive strategies during midlife, including reducing smoking, controlling diabetes mellitus, and normalizing blood pressure, could help to reduce the risk of VaD.
|
Acknowledgments |
|---|
Sources of Funding
The HAAS has been supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging (grants U01 AG019349 and R01 AG0–17155 S1), and National Heart, Lung, and Blood Institute (grant N01 HC05102). Dr Laurin is a chercheur-boursier from the Fonds de la Recherche en Santé du Québec.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006; 295: 547–553.
2. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med. 2005; 56: 249–272.[CrossRef][Medline] [Order article via Infotrieve]
3. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study: the Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999; 19: 538–545.
4. Phillips NA, Mate-Kole CC, Kirby RL. Neuropsychological function in peripheral vascular disease amputee patients. Arch Phys Med Rehabil. 1993; 74: 1309–1314.[CrossRef][Medline] [Order article via Infotrieve]
5. Phillips NA, Mate-Kole CC. Cognitive deficits in peripheral vascular disease: a comparison of mild stroke patients and normal control subjects. Stroke. 1997; 28: 777–784.
6. Waldstein SR, Tankard CF, Maier KJ, Pelletier JR, Snow J, Gardner AW, Macko R, Katzel LI. Peripheral arterial disease and cognitive function. Psychosom Med. 2003; 65: 757–763.
7. Rao R, Jackson S, Howard R. Neuropsychological impairment in stroke, carotid stenosis, and peripheral vascular disease: a comparison with healthy community residents. Stroke. 1999; 30: 2167–2173.
8. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ. 1994; 308: 1604–1608.
9. Woo J, Lynn H, Wong SY, Hong A, Tang YN, Lau WY, Lau E, Orwoll E, Kwok TC. Correlates for a low ankle-brachial index in elderly Chinese. Atherosclerosis. 2006; 186: 360–366.[CrossRef][Medline] [Order article via Infotrieve]
10. Elwood PC, Pickering J, Bayer A, Gallacher JE. Vascular disease and cognitive function in older men in the Caerphilly cohort. Age Ageing. 2002; 31: 43–48.
11. Fujiwara Y, Chaves PH, Takahashi R, Amano H, Yoshida H, Kumagai S, Fujita K, Wang DG, Shinkai S. Arterial pulse wave velocity as a marker of poor cognitive function in an elderly community-dwelling population. J Gerontol A Biol Sci Med Sci. 2005; 60: 607–612.
12. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999; 282: 40–46.
13. Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, Wehnert A, de Knijff P, Havekes LM, Grobbee DE, Van Broeckhoven C, Hofman A. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl. 1998; 53: 17–29.[Medline] [Order article via Infotrieve]
14. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke. 1996; 27: 2230–2235.
15. Kuusisto J, Koivisto K, Mykkänen L, Helkala E-L, Vanhanen M, Hänninen T, Kervinen K, Kesäniemi YA, Riekkinen PJ, Laakso M. Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997; 315: 1045–1049.
16. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002; 51: 1256–1262.
17. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002; 1: 61–77.[CrossRef][Medline] [Order article via Infotrieve]
18. Syme S, Marmot M, Kagan A, Kato H, Rhoads G. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: introduction. Am J Epidemiol. 1975; 102: 477–480.
19. White L, Petrovitch H, Ross G, Masaki K, Abbott R, Teng E, Rodriguez B, Blanchette P, Havlik R, Wergowske G, Chiu D, Foley D, Murdaugh C, Curb J. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA. 1996; 276: 955–960.
20. Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D, White LR. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994; 6: 45–58.[CrossRef][Medline] [Order article via Infotrieve]
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. revised. Washington, DC: American Psychiatric Association; 1987.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984; 34: 939–944.
23. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH, Davis DG, Nelson J, Hardman J, Curb JD, Blanchette PL, Launer LJ, Yano K, Markesbery WR. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology. 2001; 57: 226–234.
24. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 1992; 42: 473–480.
25. Curb JD, Masaki K, Rodriguez BL, Abbott RD, Burchfiel CM, Chen R, Petrovitch H, Sharp D, Yano K. Peripheral artery disease and cardiovascular risk factors in the elderly: the Honolulu Heart Program. Arterioscler Thromb Vasc Biol. 1996; 16: 1495–1500.
26. Abbott RD, Rodriguez BL, Petrovitch H, Yano K, Schatz IJ, Popper JS, Masaki KH, Ross GW, Curb JD. Ankle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program. J Clin Epidemiol. 2001; 54: 973–978.[CrossRef][Medline] [Order article via Infotrieve]
27. Abbott RD, Petrovitch H, Rodriguez BL, Yano K, Schatz IJ, Popper JS, Masaki KH, Ross GW, Curb JD. Ankle/brachial blood pressure in men >70 years of age and the risk of coronary heart disease. Am J Cardiol. 2000; 86: 280–284.[CrossRef][Medline] [Order article via Infotrieve]
28. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160–3167.
29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990; 31: 545–548.[Abstract]
30. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association September 18–20, 1992 New Orleans, Louisiana. Circulation. 1993; 88: 819–828.
31. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues J. Modelling age-specific risk: application to dementia. Stat Med. 1998; 17: 1973–1988.[CrossRef][Medline] [Order article via Infotrieve]
32. Caruana MF, Bradbury AW, Adam DJ. The validity, reliability, reproducibility and extended utility of ankle to brachial pressure index in current vascular surgical practice. Eur J Vasc Endovasc Surg. 2005; 29: 443–451.[CrossRef][Medline] [Order article via Infotrieve]
33. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation. 1995; 91: 1472–1479.
34. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998; 18: 185–192.
35. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001; 286: 1317–1324.
36. Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ. Gender and peripheral arterial disease. J Am Board Family Med. 2006; 19: 132–140.
37. Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG, Hays MA, Crum LD, Heiss G. Correlates of cognitive function in middle-aged adults: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology. 1998; 44: 95–105.[CrossRef][Medline] [Order article via Infotrieve]
38. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 14–22.
39. Singh-Manoux A, Britton AR, Marmot M. Vascular disease and cognitive function: evidence from the Whitehall II Study. J Am Geriatr Soc. 2003; 51: 1445–1450.[CrossRef][Medline] [Order article via Infotrieve]
40. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
41. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000; 21: 383–421.[CrossRef][Medline] [Order article via Infotrieve]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||